Condition (MeSH)
Uveitis, Posterior
ClinicalTrials.gov lists 82 trials for Uveitis, Posterior or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
60 of the 82 trials are tagged with Uveitis, Posterior itself; the rest are tagged with a narrower condition beneath it.
When did Uveitis, Posterior trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 2 |
| 2022 | 7 |
| 2021 | 2 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 6 |
| 2017 | 6 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Uveitis, Posterior trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 6 |
| Phase 2 | 10 |
| Phase 2/3 | 2 |
| Phase 3 | 23 |
| Phase 4 | 10 |
| Not applicable | 7 |
| Observational | 22 |
How many Uveitis, Posterior trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Completed | 40 |
| Terminated | 13 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Uveitis, Posterior trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 6 |
| Clearside Biomedical, Inc. | 5 |
| National Eye Institute (NEI) | 5 |
| Allergan | 3 |
| XOMA (US) LLC | 3 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Uveitis, Posterior? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Voclosporin | 2 |
| Prednisone | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Secukinmab | 7 |
| Bevacizumab 1 | 4 |
| Dose 2 gevokizumab | 3 |
| SHAM injection | 3 |
| Acthar low dose (40 U) | 3 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Uveitis, Posterior trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypotony of eye | 9 | 2 |
| CATARACT | 7 | 1 |
| URINARY TRACT INFECTION | 5 | 1 |
| UVEITIS | 5 | 1 |
| Uveitis (Study eye) | 5 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Uveitis, Posterior? (36)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Assessment of choriocapillaris and choroidal vascular changes in posterior uveitis using swept-source wide-field optical coherence tomography angiography. | The British journal of ophthalmology | 2024 | Yes |
| Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. | Ophthalmology | 2021 | Yes |
| Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results. | Ophthalmology | 2020 | Yes |
| Inner Retinal Microvasculature Damage Correlates With Outer Retinal Disruption During Remission in Behçet's Posterior Uveitis by Optical Coherence Tomography Angiography. | Investigative ophthalmology & visual science | 2018 | Yes |
| Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. | JAMA ophthalmology | 2017 | Yes |
Showing 5 of 36 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Posterior uveitis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Posterior uveitis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Posterior uveitis | 280892 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Posterior uveitis | 280892 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.